J
Jean Luc Harousseau
Researcher at University of Nantes
Publications - 82
Citations - 16270
Jean Luc Harousseau is an academic researcher from University of Nantes. The author has contributed to research in topics: Multiple myeloma & Bortezomib. The author has an hindex of 46, co-authored 82 publications receiving 14925 citations. Previous affiliations of Jean Luc Harousseau include University of Pennsylvania & Hotel Dieu Hospital.
Papers
More filters
Journal ArticleDOI
Monoclonal gammopathy of undetermined significance: a consensus statement
James R. Berenson,Kenneth C. Anderson,Robert A. Audell,Ralph V. Boccia,Morton Coleman,Meletios A. Dimopoulos,Matthew T. Drake,Rafael Fonseca,Jean Luc Harousseau,Douglas E. Joshua,Sagar Lonial,Ruben Niesvizky,Antonio Palumbo,G. David Roodman,Jesús F. San-Miguel,Seema Singhal,Donna M. Weber,Maurizio Zangari,Eric Wirtschafter,Ori Yellin,Robert A. Kyle +20 more
TL;DR: The following consensus statement outlines the conclusions and marks the first time that a consensus statement for the screening and treatment of MGUS has been clearly stated.
Journal Article
CD28, a marker associated with tumoral expansion in multiple myeloma.
Nelly Robillard,Gaëtan Jego,Catherine Pellat-Deceunynck,Danielle Pineau,Denis Puthier,Marie-Paule Mellerin,Sophie Barillé,M. J. Rapp,Jean Luc Harousseau,Martine Amiot,Régis Bataille +10 more
TL;DR: The data show that an aggressive compartment of CD28+ and CD86+ myeloma cells emerges during the course of MM in vivo, indicating that CD28 could be aberrantly expressed on highly malignant (possibly mutated) myel cancer cells.
Journal ArticleDOI
Therapy-related acute promyelocytic leukemia: a report on 16 cases.
L. Detourmignies,Sylvie Castaigne,Anne-Marie Stoppa,Jean Luc Harousseau,A Sadoun,Maud Janvier,J L Demory,Miguel A. Sanz,Raanan Berger,Francis Bauters +9 more
TL;DR: The findings suggest that tAPL is not exceptional, and usually has several features in common with other types of therapy-related AML with specific karyotype, including solid tumor rather than hematologic malignancy as primary tumor, short interval of development, absence of known preleukemic phase.
Journal ArticleDOI
Maintenance Treatment with Lenalidomide After Transplantation for MYELOMA: Final Analysis of the IFM 2005-02.
Michel Attal,Valerie cances Lauwers,Gerald Marit,Denis Caillot,Thierry Facon,Cyrille Hulin,Philippe Moreau,Claire Mathiot,Murielle Roussel,Catherine Payen,Hervé Avet-Loiseau,Jean Luc Harousseau +11 more
TL;DR: The IFM 2005-02 trial demonstrates that lenalidomide is an effective and well tolerated maintenance treatment after transplantation for multiple myeloma patients.
Journal ArticleDOI
Thalidomide in patients with advanced multiple myeloma: a study of 83 patients--report of the Intergroupe Francophone du Myélome (IFM).
Ibrahim Yakoub-Agha,Michel Attal,Charles Dumontet,Delannoy,Philippe Moreau,Christian Berthou,Thierry Lamy,Bernard Grosbois,C. Dauriac,Dorvaux,J.-O. Bay,Mathieu Monconduit,Jean Luc Harousseau,C. Duguet,A. Duhamel,Thierry Facon +15 more
TL;DR: Thalidomide is an effective treatment for patients with advanced myeloma, in particular, who have no poor-risk features, and the poor results achieved by the other patients emphasize the need for prospective protocols using thalidomides in combination, especially with dexamethasone.